‘Library’ of de-prioritised pharma compounds available for researchers
UK scientists can apply for MRC funding to use any of the compounds in medical research studies to investigate the underlying mechanics of disease...
List view / Grid view
UK scientists can apply for MRC funding to use any of the compounds in medical research studies to investigate the underlying mechanics of disease...
16 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The mucosa forms a unique immunological antibody memory that does not occur if the vaccine is given by injection, says a study from Sahlgrenska Academy...
15 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Researchers at VIB and Ghent University have discovered an important mechanism of sepsis, an overreaction of the body’s immune system to an infection...
15 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Grants of more than €5 million, predominantly from the EU, will be used to develop a new imaging device for the diagnosis of breast cancer...
13 September 2016 | By SMi
SMi Reports (13.09. 2016, London, UK): Alexion, BioMarin, Chiesi, MHRA, NICE to meet in London in October to discuss updates in the orphan drug landscape...
8 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Compound kushen injection (CKI) has been used for years in Chinese clinics as an adjunct to western chemotherapy. Researchers used next generation...
8 September 2016 | By Caroline Richards, Editor, European Pharmaceutical Review & Drug Target Review
In a mouse model of inflammation (thioglycollate-induced peritonitis), PQ912 had an effect on recruitment of macrophages and eosinophils, and levels of chemokines and lipid mediators, which the company believes makes QC inhibition attractive for further evaluation as potential anti-inflammatory drug and/or resolution promoting agent...
8 September 2016 | By Niamh Louise Marriott, Digital Content Producer
A new research funding agreement aims to address people with severe type 1 diabetes (T1D) who are hypoglycemia unaware, a condition in which a person with...
8 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Through a process involving vitamin A, researchers from Imperial College London observed that it was possible to switch off pancreatic stellate cells...
7 September 2016 | By Niamh Louise Marriott, Digital Content Producer
HSRx expects to begin human trials early in 2017 and will seek accelerated drug approval from the U.S. Food & Drug Administration...
6 September 2016 | By Niamh Louise Marriott, Digital Content Producer
This research group is seeking the potential to unravel novel methods to remove bacterial biofilms from oral surfaces. Oral biofilms consist of a large variety of microorganisms embedded in a complex and robust extracellular matrix...
6 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The funding will advance the ongoing development of Rigontec’s RIG-I agonist platform targeting oncological, anti-infective and inflammatory indications as well as accelerate the progress of lead candidate RGT100 towards the clinic...
6 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Researchers sprayed a dye on oesophageal tissue samples taken from people with Barrett’s oesophagus – a condition that risk cancer development...
5 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The loss of CHD1, one of the most mutated genes in prostate tumours, sensitises human prostate cancer cells to different drugs, a biomarker for...
2 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The blood test detects mutations to a gene called oestrogen receptor 1, or ESR1, which indicate that receptors for the female hormone oestrogen in the cancer cells, which are usually driven by the hormone, have evolved to stay permanently switched on without it – meaning hormonal treatments that block oestrogen…